ranolazine has been researched along with Disease Models, Animal in 68 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (22.06) | 29.6817 |
| 2010's | 44 (64.71) | 24.3611 |
| 2020's | 9 (13.24) | 2.80 |
| Authors | Studies |
|---|---|
| Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Arafune, T; Dobrev, D; Honjo, H; Kodama, I; Makita, N; Nattel, S; Niwa, R; Sakuma, I; Takanari, H; Tomii, N; Tsuji, Y; Tsuneyama, K; Yamazaki, M | 1 |
| Abdala, AP; Charles, I; Cheng, H; Hancox, JC; James, AF | 1 |
| Banach, M; Borowicz-Reutt, K | 1 |
| de Lima Conceição, MR; Leal-Silva, P; Roman-Campos, D; Teixeira-Fonseca, JL | 1 |
| He, XN; Li, H; Wang, GT; Yu, ZQ | 1 |
| Han, J; Lu, YX; Shuai, XX; Su, GH; Wang, YH; Zhao, HL | 1 |
| Belardinelli, L; Dhalla, A; Opačić, D; Schotten, U; van Hunnik, A; Verheule, S; Zeemering, S | 1 |
| Bu, P; Chen, T; Liu, L; Ma, C; Qi, Y; Ti, Y; Yang, Y; Zhang, C | 1 |
| Azam, MA; Kusha, M; Labos, C; Lai, PF; Massé, S; Nair, GK; Nanthakumar, K; Tan, NS; Zamiri, N | 1 |
| Laviolette, SR; Rosen, LG; Rushlow, WJ | 1 |
| Buhl, R; Carstensen, H; Flethøj, M; Haugaard, MM; Hesselkilde, EZ; Jespersen, T; Kanters, JK; Kjær, L; Pehrson, S | 1 |
| Ren, Z; Teng, S; Zhao, K | 1 |
| Fukaya, H; Laurita, KR; Piktel, JS; Plummer, BN; Rosenbaum, DS; Wan, X; Wilson, LD | 1 |
| Buhl, R; Carlson, J; Carstensen, H; Flethøj, M; Haugaard, MM; Hesselkilde, EZ; Jespersen, T; Pehrson, S; Platonov, PG | 1 |
| Altun, S; Bugan, I; Djamgoz, MBA; Dodson, A; Foster, CS; Fraser, SP; Karagoz, Z; Kaya, H; Kucuk, S | 1 |
| Aidonidis, I; Dipla, K; Hatziefthimiou, A; Moschovidis, V; Simopoulos, V; Stamatiou, R; Stravela, S | 1 |
| Bui-Xuan, B; Chevalier, P; Dehina, L; Descotes, J; Dizerens, N; Mamou, Z; Romestaing, C; Timour, Q | 1 |
| Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T | 1 |
| Aistrup, GL; Belardinelli, L; Beussink, L; Chirayil, N; El-Bizri, N; Gupta, DK; Kelly, JE; Misener, S; Mongkolrattanothai, T; Nahhas, A; Ng, J; O'Toole, MJ; Rajamani, S; Reddy, M; Shah, SJ; Shryock, JC; Singh, N; Wasserstrom, JA | 1 |
| Fedida, D; Lin, S; McAfee, D; Pourrier, M; Williams, S | 1 |
| Belardinelli, L; Dhalla, AK; Galanopoulos, G; Kostakou, E; Mantzouratou, P; Mourouzis, I; Pantos, C | 1 |
| Canovi, M; Fumagalli, F; Gobbi, M; Latini, R; Letizia, T; Li, Y; Masson, S; Novelli, D; Ristagno, G; Rocchetti, M; Russo, I; Staszewsky, L; Veglianese, P; Zaza, A | 1 |
| Antzelevitch, C; Barajas-Martínez, H; Belardinelli, L; Burashnikov, A; Cordeiro, JM; Di Diego, JM; Hu, D; Kornreich, BG; Moise, NS; Zygmunt, AC | 1 |
| Belardinelli, L; Bhimani, AA; Khrestian, CM; Lee, S; Sadrpour, SA; Waldo, AL; Yasuda, T; Zeng, D | 1 |
| Hale, SL; Kloner, RA | 3 |
| Cho, SR; Diamond, I; Gould, HJ; Hernandez, C; Paul, D; Soignier, RD; Taylor, BK | 1 |
| Alemanni, M; Altomare, C; Barile, L; Cornaghi, L; Gobbi, M; Latini, R; Lucchetti, J; Mostacciuolo, G; Rizzetto, R; Rocchetti, M; Ronchi, C; Russo, I; Sala, L; Staszewsky, LI; Zambelli, V; Zaza, A | 1 |
| Chiellini, G; Frascarelli, S; Ghelardoni, S; Zucchi, R | 1 |
| Diness, JG; Grunnet, M; Jespersen, T; Kirchhoff, JE; Sheykhzade, M | 1 |
| Calderón-Sánchez, EM; Domínguez-Rodríguez, A; Gómez, AM; Jiménez-Navarro, MF; López-Haldón, J; Ordóñez, A; Smani, T | 1 |
| Bronsart, LL; Contag, CH; Stokes, C | 1 |
| Berrino, L; Cappetta, D; Ciuffreda, LP; De Angelis, A; Donniacuo, M; Esposito, G; Ferraiolo, FA; Piegari, E; Rinaldi, B; Rivellino, A; Rossi, F; Russo, R; Urbanek, K | 1 |
| Bögeholz, N; Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Güner, F; Kochhäuser, S; Leitz, P; Pott, C | 1 |
| Balijepalli, RC; Belardinelli, L; Hacker, TA; Markandeya, YS; Tsubouchi, T; Wolff, MR | 1 |
| Bargelli, V; Bartolucci, G; Belardinelli, L; Cerbai, E; Coppini, R; Crocini, C; Ferrantini, C; Gentile, F; Laurino, A; Mazzoni, L; Mugelli, A; Olivotto, I; Pioner, JM; Poggesi, C; Rotellini, M; Sacconi, L; Santini, L; Tardiff, J; Tesi, C | 1 |
| Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC | 1 |
| Aass, HC; Aronsen, JM; Brørs, O; Haugen, E; Møller, AS; Mørk, HK; Pedersen, J; Sejersted, OM; Sharikabad, MN; Sjaastad, I | 1 |
| Barone, L; Crea, F; Di Monaco, A; Lamendola, P; Lanza, GA; Pisanello, C | 1 |
| Acar, M; Belardinelli, L; Carvas, M; Kumar, K; Nascimento, BC; Nearing, BD; Verrier, RL | 1 |
| Belardinelli, L; Bhandari, A; Dhalla, AK; Dow, J; Kloner, RA; Shryock, JC; Wang, WQ | 1 |
| Acar, M; Belardinelli, L; Carvas, M; Nascimento, BC; Nearing, BD; Verrier, RL | 1 |
| Chatterjee, S; Ilayaraja, M; Majumder, S; Seerapu, HR; Siamwala, JH; Sinha, S | 1 |
| Antzelevitch, C; Belardinelli, L; Burashnikov, A; Di Diego, JM; Sicouri, S | 1 |
| Belardinelli, L; Datti, IP; Nanbu, DY; Nearing, BD; Nieminen, T; Pegler, JR; Tavares, CA; Vaz, GR; Verrier, RL | 1 |
| Belardinelli, L; Bers, DM; Grandi, E; Li, H; Luo, A; Ma, J; Shryock, JC; Wang, C; Wu, L; Zhang, P | 1 |
| Chartier, D; Comtois, P; Duverger, JE; Fabritz, L; Kirchhof, P; Lemoine, MD; Nattel, S; Naud, P; Qi, XY | 1 |
| Abramson, JJ; Kozhevnikov, D; Mantravadi, R; Owen, LJ; Parikh, A; Puglisi, JL; Roche, MA; Salama, G; Ye, Y | 1 |
| Belardinelli, L; Dudley, SC; Gu, L; Jeong, EM; Kumar, P; Lardin, HA; Liu, H; Lovelock, JD; Monasky, MM; Patel, BG; Pokhrel, N; Solaro, RJ; Sorescu, D; Taglieri, DM; Zeng, D | 1 |
| Atack, TC; Hall, L; Lowe, JS; Roden, DM; Stroud, DM; Yang, T | 1 |
| Bernus, O; Boycott, HE; Boyle, JP; Dallas, ML; Duke, A; Elies, J; Milligan, CJ; Peers, C; Reboul, C; Richard, S; Scragg, JL; Steele, DS; Thireau, J; Yang, Z | 1 |
| Belardinelli, L; Kanas, AF; Nearing, BD; Pagotto, VP; Sobrado, MF; Verrier, RL; Zeng, D | 1 |
| Aiba, T; Begley, MJ; Boström, P; Cantley, LC; Das, S; del Monte, F; Ellinor, PT; Graham, EL; Hessler, K; Knight, AC; Morissette, MR; Ottaviano, FG; Quintero, PA; Rosenberg, M; Rosenzweig, A; Tomaselli, GF; Xiao, C | 1 |
| Greer-Short, A; Poelzing, S; Radwański, PB | 1 |
| Belardinelli, L; Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Osada, N; Rajamani, S; Uphaus, T | 1 |
| Clauß, C; Eckardt, L; Frommeyer, G; Kaese, S; Milberg, P; Pott, C; Schmidt, M; Stypmann, J | 1 |
| Belardinelli, L; Breithardt, G; Eckardt, L; Frommeyer, G; Grundmann, F; Milberg, P; Osada, N; Rajamani, S; Stypmann, J | 1 |
| Blackburn, B; Chandler, MP; Morita, H; Roth, BA; Sabbah, HN; Stanley, WC; Suzuki, G; Wolff, A | 1 |
| Biesiadecki, BJ; Blackburn, B; Chandler, MP; Chaudhry, P; Mishima, T; Nass, O; Sabbah, HN; Stanley, WC; Suzuki, G; Wolff, A | 1 |
| Antzelevitch, C; Belardinelli, L; Li, Y; Shryock, JC; Song, Y; Wu, L | 1 |
| Belardinelli, L; Sabbah, HN; Undrovinas, AI; Undrovinas, NA | 1 |
| Antzelevitch, C; Belardinelli, L; Glass, A; Goodrow, RJ; Sicouri, S; Timothy, KW; Zygmunt, AC | 1 |
| Barry, WH; Yamada, S; Zhang, XQ | 1 |
| Belardinelli, L; Hale, SL; Kloner, RA; Shryock, JC; Sweeney, M | 1 |
| Blackburn, B; Thiemermann, C; Zacharowski, K | 1 |
3 review(s) available for ranolazine and Disease Models, Animal
| Article | Year |
|---|---|
Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models.
Topics: Acetanilides; Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Disease Models, Animal; Myocardial Infarction; Necrosis; Piperazines; Ranolazine; Reperfusion Injury; Ventricular Function, Left | 2014 |
[Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications].
Topics: Acetanilides; Acute Coronary Syndrome; Angina Pectoris; Animals; Apoptosis; Cell Death; Collateral Circulation; Disease Models, Animal; Humans; Ischemic Preconditioning, Myocardial; Meta-Analysis as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Oxygen Consumption; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Trimetazidine; Vasodilator Agents | 2009 |
Late sodium current inhibition as a new cardioprotective approach.
Topics: Acetanilides; Angina Pectoris; Animals; Blood Pressure; Disease Models, Animal; Enzyme Inhibitors; Heart Rate; Humans; Myocardial Infarction; Myocytes, Cardiac; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Sodium Channels | 2008 |
65 other study(ies) available for ranolazine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Rotors anchored by refractory islands drive torsades de pointes in an experimental model of electrical storm.
Topics: Action Potentials; Animals; Atrioventricular Block; Defibrillators, Implantable; Disease Models, Animal; Long QT Syndrome; Rabbits; Ranolazine; Tachycardia, Ventricular; Torsades de Pointes | 2022 |
Delayed Ventricular Repolarization and Sodium Channel Current Modification in a Mouse Model of Rett Syndrome.
Topics: Animals; Disease Models, Animal; Long QT Syndrome; Male; Mice; Ranolazine; Rett Syndrome; Sodium; Sodium Channels | 2022 |
Ranolazine Interacts Antagonistically with Some Classical Antiepileptic Drugs-An Isobolographic Analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Electroshock; Epilepsy; Mice; Phenobarbital; Phenytoin; Ranolazine; Seizures | 2022 |
Ranolazine exerts atrial antiarrhythmic effects in a rat model of monocrotaline-induced pulmonary hypertension.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Heart Atria; Hypertension, Pulmonary; Monocrotaline; Ranolazine; Rats; Rats, Wistar | 2023 |
Effects of ranolazine on cardiac function in rats with heart failure.
Topics: Animals; Apoptosis; Cardiovascular Agents; Cells, Cultured; Disease Models, Animal; Heart Failure; Injections, Intraperitoneal; Male; Ranolazine; Rats; Rats, Wistar | 2019 |
18β-Glycyrrhetinic Acid Improves Cardiac Diastolic Function by Attenuating Intracellular Calcium Overload.
Topics: Animals; Calcium; Cnidarian Venoms; Diastole; Disease Models, Animal; Echocardiography; Glycyrrhetinic Acid; Hemodynamics; Male; Microscopy, Confocal; Myocardial Reperfusion Injury; Random Allocation; Ranolazine; Rats; Tablets; Treatment Outcome | 2020 |
Electrophysiological effects of ranolazine in a goat model of lone atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Remodeling; Disease Models, Animal; Female; Goats; Heart Atria; Ranolazine; Sodium Channel Blockers | 2021 |
Ranolazine alleviates contrast-associated acute kidney injury through modulation of calcium independent oxidative stress and apoptosis.
Topics: Acute Kidney Injury; Animals; Apoptosis; Blood Urea Nitrogen; Calcium; Contrast Media; Creatinine; Disease Models, Animal; Hepatitis A Virus Cellular Receptor 1; Kidney; Lipocalin-2; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Ranolazine; Renal Artery | 2021 |
Effects of Late Sodium Current Blockade on Ventricular Refibrillation in a Rabbit Model.
Topics: Animals; Calcium; Calcium Channels; Disease Models, Animal; Electric Countershock; Heart Arrest; Logistic Models; Pyridines; Rabbits; Random Allocation; Ranolazine; Reference Values; Sodium Channel Blockers; Sodium Channels; Statistics, Nonparametric; Triazoles; Ventricular Fibrillation | 2017 |
Opiate exposure state controls dopamine D3 receptor and cdk5/calcineurin signaling in the basolateral amygdala during reward and withdrawal aversion memory formation.
Topics: Analgesics, Opioid; Animals; Association Learning; Avoidance Learning; Basolateral Nuclear Complex; Calcineurin; Conditioning, Psychological; Cyclin-Dependent Kinase 5; Disease Models, Animal; Heroin; Male; Memory; Opioid-Related Disorders; Ranolazine; Rats, Sprague-Dawley; Receptors, Dopamine D3; Reward; Signal Transduction; Spatial Behavior; Substance Withdrawal Syndrome | 2017 |
Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Drug Combinations; Female; Heart Rate; Horses; Infusions, Intravenous; Male; Phenethylamines; Ranolazine; Sulfonamides | 2018 |
Vagal Stimulation Facilitates Improving Effects of Ranolazine on Cardiac Function in Rats with Chronic Ischemic Heart Failure.
Topics: Animals; Chronic Disease; Cytokines; Disease Models, Animal; Heart Failure; Male; Myocardial Ischemia; Nerve Tissue Proteins; Norepinephrine; Ranolazine; Rats; Rats, Sprague-Dawley; Vagus Nerve Stimulation; Ventricular Function, Left | 2018 |
Arrhythmogenic cardiac alternans in heart failure is suppressed by late sodium current blockade by ranolazine.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Disease Models, Animal; Dogs; Heart Conduction System; Heart Failure; Myocytes, Cardiac; Optical Imaging; Ranolazine; Sodium Channel Blockers | 2019 |
Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Horses; Male; Phenethylamines; Potassium Channel Blockers; Ranolazine; Sodium Channel Blockers; Sulfonamides; Time Factors | 2019 |
Anti-metastatic effect of ranolazine in an in vivo rat model of prostate cancer, and expression of voltage-gated sodium channel protein in human prostate.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; NAV1.7 Voltage-Gated Sodium Channel; Prostate; Prostatic Neoplasms; Ranolazine; Rats; Tissue Array Analysis; Voltage-Gated Sodium Channel Blockers | 2019 |
Dose-Dependent Effects of Ranolazine on Reentrant Ventricular Arrhythmias Induced After Subacute Myocardial Infarction in Rabbits.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heart Rate; Male; Myocardial Infarction; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Tachycardia, Ventricular; Time Factors; Ventricular Fibrillation | 2020 |
Protective effects of ranolazine and propranolol, alone or combined, on the structural and functional alterations of cardiomyocyte mitochondria in a pig model of ischemia/reperfusion.
Topics: Acetanilides; Animals; Calcium; Cardiotonic Agents; Disease Models, Animal; Drug Therapy, Combination; Heart Rate; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxygen Consumption; Piperazines; Propranolol; Ranolazine; Reactive Oxygen Species; Sus scrofa | 2014 |
Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dronedarone; Drug Therapy, Combination; Female; Piperazines; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Sotalol | 2013 |
Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat.
Topics: Acetanilides; Animals; Calcium Channels, L-Type; Calcium Signaling; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Rats; Rats, Inbred SHR; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium; Sodium Channel Blockers; Sodium Channels; Sodium-Calcium Exchanger; Time Factors; Ultrasonography | 2013 |
Ranolazine improves diastolic function in spontaneously hypertensive rats.
Topics: Acetanilides; Aging; Animals; Blood Pressure; Calcium; Cells, Cultured; Diastole; Disease Models, Animal; Dobutamine; Enzyme Inhibitors; Hypertension; In Vitro Techniques; Male; Myocytes, Cardiac; Piperazines; Ranolazine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrodotoxin; Ventricular Dysfunction, Left | 2014 |
The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats.
Topics: Acetanilides; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Echocardiography; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Heart Function Tests; Insulin; Male; Myocardial Infarction; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Ranolazine; Rats; Rats, Wistar; Treatment Outcome; Ventricular Function, Left | 2014 |
Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest.
Topics: Acetanilides; Animals; Cardiomyopathies; Cardiopulmonary Resuscitation; Central Nervous System; Disease Models, Animal; Enzyme Inhibitors; Heart Arrest; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers; Treatment Outcome; Ventricular Dysfunction, Left | 2014 |
Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.
Topics: Acetanilides; Action Potentials; Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Enzyme Inhibitors; Follow-Up Studies; Heart Atria; Heart Conduction System; Heart Failure; Heart Ventricles; Myocytes, Cardiac; Patch-Clamp Techniques; Piperazines; Ranolazine; Sodium Channel Blockers | 2014 |
Ranolazine terminates atrial flutter and fibrillation in a canine model.
Topics: Acetanilides; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Brugada Syndrome; Cardiac Conduction System Disease; Disease Models, Animal; Dogs; Electrocardiography; Enzyme Inhibitors; Heart Conduction System; Heart Rate; Injections, Intravenous; Piperazines; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2014 |
Ranolazine attenuates mechanical allodynia associated with demyelination injury.
Topics: Acetanilides; Animals; Demyelinating Diseases; Disease Models, Animal; Enzyme Inhibitors; Hyperalgesia; Male; Neuralgia; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Sciatic Nerve | 2014 |
Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Topics: Acetanilides; Animals; Calcium Signaling; Collagen; Disease Models, Animal; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Membrane Potentials; Monocrotaline; Myocytes, Cardiac; Myosin Heavy Chains; Piperazines; Pulmonary Artery; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium; Sodium Channel Blockers; Sodium Channels; Time Factors; Vascular Remodeling; Vascular Resistance; Ventricular Function, Right; Ventricular Remodeling | 2014 |
Cardioprotection by ranolazine in perfused rat heart.
Topics: Acetanilides; Animals; Calcium; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Myocardial Reperfusion Injury; Oxygen Consumption; Piperazines; Ranolazine; Rats; Rats, Wistar; Ryanodine; Sarcoplasmic Reticulum | 2014 |
Synergistic antiarrhythmic effect of combining inhibition of Ca²⁺-activated K⁺ (SK) channels and voltage-gated Na⁺ channels in an isolated heart model of atrial fibrillation.
Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Female; Flecainide; Guinea Pigs; Piperazines; Ranolazine; Small-Conductance Calcium-Activated Potassium Channels; Voltage-Gated Sodium Channel Blockers; Voltage-Gated Sodium Channels | 2015 |
Cardioprotective Effect of Ranolazine in the Process of Ischemia-reperfusion in Adult Rat Cardiomyocytes.
Topics: Animals; Calcium; Disease Models, Animal; Intracellular Fluid; Male; Microscopy, Confocal; Myocardial Reperfusion Injury; Myocytes, Cardiac; Ranolazine; Rats; Rats, Wistar; Sodium Channel Blockers | 2016 |
Chemiluminescence Imaging of Superoxide Anion Detects Beta-Cell Function and Mass.
Topics: Animals; Cell Respiration; Diabetes Mellitus, Experimental; Disease Models, Animal; Glucose; HeLa Cells; Humans; Hyperglycemia; Imaging, Three-Dimensional; Imidazoles; Insulin-Secreting Cells; Luminescent Measurements; Mice, Inbred NOD; Organ Size; Pyrazines; Pyridines; Ranolazine; Superoxides | 2016 |
Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Ranolazine; Rats; Rats, Inbred Dahl; Signal Transduction; Stroke Volume; Treatment Outcome; Ventricular Remodeling | 2016 |
Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome.
Topics: Action Potentials; Animals; Anisoles; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Disease Models, Animal; Electrocardiography; Heart Rate; Isolated Heart Preparation; Pinacidil; Pyrrolidines; Rabbits; Ranolazine; Sodium Channel Blockers; Time Factors; Ventricular Fibrillation | 2016 |
Inhibition of late sodium current attenuates ionic arrhythmia mechanism in ventricular myocytes expressing LaminA-N195K mutation.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Disease Models, Animal; Heart Ventricles; Lamin Type A; Mice; Mutation, Missense; Myocytes, Cardiac; Ranolazine; Sodium Channel Blockers; Sodium Channels | 2016 |
Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Topics: Animals; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Echocardiography, Doppler; Excitation Contraction Coupling; Genetic Predisposition to Disease; Heart Rate; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Membrane Potentials; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Mutation; Myocardial Contraction; Myocytes, Cardiac; Phenotype; Ranolazine; Sodium; Sodium Channel Blockers; Time Factors; Troponin T; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit.
Topics: Acetanilides; Animals; Blood Pressure; Cardiovascular Agents; Coronary Circulation; Disease Models, Animal; Heart Rate; Male; Myocardial Infarction; Myocardial Reperfusion Injury; No-Reflow Phenomenon; Piperazines; Rabbits; Ranolazine | 2008 |
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Disease Models, Animal; Disease Progression; Dogs; Drug Therapy, Combination; Enalapril; Heart Failure; Metoprolol; Myocardium; Piperazines; Proteins; Ranolazine; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Cardiomyocytes from postinfarction failing rat hearts have improved ischemia tolerance.
Topics: Acetanilides; Adenosine Triphosphate; Animals; Calcium; Cell Death; Cell Hypoxia; Cells, Cultured; Disease Models, Animal; Heart Failure; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxygen; Piperazines; Potassium; Ranolazine; Rats; Rats, Wistar; Rubidium Radioisotopes; Sodium; Sodium Channel Blockers; Sodium-Calcium Exchanger; Sodium-Potassium-Exchanging ATPase; Time Factors | 2009 |
Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.
Topics: Acetanilides; Acetylcholine; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Disease Models, Animal; Electrophysiologic Techniques, Cardiac; Female; Heart Atria; Heart Conduction System; Infusions, Intravenous; Male; Piperazines; Ranolazine; Refractory Period, Electrophysiological; Swine; Time Factors | 2009 |
Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.
Topics: Acetanilides; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Infusions, Intravenous; Injections, Intravenous; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Time Factors; Ventricular Fibrillation | 2009 |
Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart.
Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Disease Models, Animal; Female; Injections; Male; Piperazines; Ranolazine; Refractory Period, Electrophysiological; Swine; Time Factors; Ventricular Fibrillation | 2010 |
Chick embryo partial ischemia model: a new approach to study ischemia ex vivo.
Topics: Acetanilides; Animals; Apoptosis; Blood Vessels; Cell Proliferation; Cell Survival; Chick Embryo; Creatine Kinase, MB Form; Disease Models, Animal; Edema; Endothelial Cells; Glutathione; Goats; Health; Hypoxia-Inducible Factor 1, alpha Subunit; Ischemia; Myocardium; Neovascularization, Pathologic; Organ Specificity; Piperazines; Ranolazine; Reactive Oxygen Species; Time Factors; Vascular Surgical Procedures | 2010 |
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.
Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Dronedarone; Drug Synergism; Drug Therapy, Combination; Piperazines; Ranolazine | 2010 |
Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model.
Topics: Acetanilides; Animals; Coronary Circulation; Coronary Stenosis; Disease Models, Animal; Electrophysiologic Techniques, Cardiac; Enzyme Inhibitors; Male; Piperazines; Ranolazine; Severity of Illness Index; Treatment Outcome; Ventricular Fibrillation | 2011 |
Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Bradycardia; Disease Models, Animal; Enzyme Inhibitors; Female; Heart Rate; Long QT Syndrome; Models, Cardiovascular; Myocardial Contraction; Myocytes, Cardiac; Patch-Clamp Techniques; Piperazines; Piperidines; Pyridines; Rabbits; Ranolazine; Sodium; Sodium Channel Blockers; Sodium Channels; Tetrodotoxin; Torsades de Pointes | 2011 |
Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model.
Topics: Acetanilides; Action Potentials; Animals; Arrhythmias, Cardiac; Disease Models, Animal; Heart Atria; Long QT Syndrome; Male; Mice; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Sodium Channels | 2011 |
Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.
Topics: Acetanilides; Action Potentials; Animals; Disease Models, Animal; Electrophysiologic Techniques, Cardiac; Enzyme Inhibitors; Female; Follow-Up Studies; Long QT Syndrome; Myocardium; Piperazines; Rabbits; Ranolazine; Ryanodine Receptor Calcium Release Channel; Torsades de Pointes; Treatment Outcome | 2012 |
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity.
Topics: Acetanilides; Animals; Calcium; Desoxycorticosterone; Diastole; Disease Models, Animal; Enzyme Inhibitors; Heart Failure, Diastolic; Mice; Mineralocorticoids; Myocardial Contraction; Myocytes, Cardiac; Myofibrils; Oxidative Stress; Piperazines; Ranolazine; Sodium; Ventricular Dysfunction, Left | 2012 |
Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice.
Topics: Acetanilides; Action Potentials; Animals; Cnidarian Venoms; Disease Models, Animal; Electrocardiography; Female; Genetic Predisposition to Disease; Humans; Long QT Syndrome; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Risk Factors; Sex Factors; Tachycardia, Ventricular; Time Factors | 2012 |
Carbon monoxide induces cardiac arrhythmia via induction of the late Na+ current.
Topics: Acetanilides; Action Potentials; Animals; Arrhythmias, Cardiac; Calcium Signaling; Carbon Monoxide; Carbon Monoxide Poisoning; Cell Culture Techniques; Disease Models, Animal; Environmental Exposure; Enzyme Inhibitors; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Piperazines; Ranolazine; Rats; Rats, Wistar; Voltage-Gated Sodium Channels | 2012 |
Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia.
Topics: Acetanilides; Amiodarone; Animals; Atrial Fibrillation; Chromatography, High Pressure Liquid; Disease Models, Animal; Dronedarone; Drug Therapy, Combination; Electrocardiography; Hemodynamics; Piperazines; Ranolazine; Swine; Tachycardia, Ventricular | 2013 |
Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling.
Topics: Acetanilides; Animals; Cardiomegaly, Exercise-Induced; Cardiomyopathy, Dilated; Consensus Sequence; Disease Models, Animal; Electrocardiography; Enzyme Induction; Heart Failure; Humans; Hypertension; Immediate-Early Proteins; Ion Channel Gating; Mice; Mice, Inbred C57BL; Mice, Transgenic; NAV1.5 Voltage-Gated Sodium Channel; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Interaction Mapping; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Ranolazine; Sodium Channel Blockers; Tachycardia, Ventricular; Ventricular Remodeling | 2012 |
Inhibition of Na+ channels ameliorates arrhythmias in a drug-induced model of Andersen-Tawil syndrome.
Topics: Acetanilides; Action Potentials; Andersen Syndrome; Animals; Calcium Channels; Cytosol; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Guinea Pigs; Male; Piperazines; Pyridinium Compounds; Random Allocation; Ranolazine; Sensitivity and Specificity; Sodium Channels; Sodium-Calcium Exchanger; Tachycardia, Ventricular | 2013 |
Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Female; Heart Conduction System; Heart Ventricles; Piperazines; Rabbits; Ranolazine; Tachycardia, Ventricular | 2012 |
Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure.
Topics: Acetanilides; Acetylcholine; Animals; Atrial Fibrillation; Disease Models, Animal; Electrocardiography; Enzyme Inhibitors; Female; Heart Conduction System; Heart Failure; Isoproterenol; Piperazines; Rabbits; Ranolazine; Signal Processing, Computer-Assisted | 2012 |
New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Heart Failure; Piperazines; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Sotalol; Ventricular Fibrillation | 2012 |
Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure.
Topics: Acetanilides; Animals; Cardiotonic Agents; Chronic Disease; Coronary Circulation; Disease Models, Animal; Dobutamine; Dogs; Drug Administration Schedule; Fatty Acids, Nonesterified; Glucose; Heart; Heart Failure; Heart Rate; Lactic Acid; Myocardium; Oxygen Consumption; Piperazines; Ranolazine; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |
Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acetanilides; Acetyl-CoA C-Acyltransferase; Animals; Carbon-Carbon Double Bond Isomerases; Chronic Disease; Disease Models, Animal; Dogs; Enoyl-CoA Hydratase; Enzyme Inhibitors; Heart Failure; Heart Ventricles; Hemodynamics; Injections, Intravenous; Models, Cardiovascular; Piperazines; Racemases and Epimerases; Radiography; Ranolazine; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2002 |
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Female; Guinea Pigs; In Vitro Techniques; Long QT Syndrome; Male; Piperazines; Ranolazine | 2004 |
Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.
Topics: Acetanilides; Action Potentials; Animals; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Heart Failure; Heart Ventricles; Ion Channel Gating; Membrane Potentials; Myocardial Contraction; Myocytes, Cardiac; Piperazines; Ranolazine; Sodium; Sodium Channels; Ventricular Dysfunction, Left | 2006 |
Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit.
Topics: Acetanilides; Animals; Blood Pressure; Disease Models, Animal; Heart Rate; Male; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardial Stunning; Piperazines; Rabbits; Random Allocation; Ranolazine; Sodium Channel Blockers; Stroke Volume; Time Factors; Ventricular Function, Left; Ventricular Pressure | 2006 |
Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Acetanilides; Action Potentials; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Calcium Channel Agonists; Disease Models, Animal; Dogs; Electrocardiography; Endocardium; Enzyme Inhibitors; Heart Ventricles; Long QT Syndrome; Myocytes, Cardiac; Patch-Clamp Techniques; Pericardium; Piperazines; Ranolazine; Tachycardia, Ventricular; Torsades de Pointes; Ventricular Premature Complexes | 2007 |
Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia.
Topics: Acetanilides; Animals; Calcium; Cations, Divalent; Cations, Monovalent; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; In Vitro Techniques; Myocardial Ischemia; Myocytes, Cardiac; Oxidative Stress; Piperazines; Rabbits; Ranolazine; Sodium; Thiourea | 2008 |
Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.
Topics: Acetanilides; Animals; Blood Pressure; Coronary Disease; Coronary Vessels; Disease Models, Animal; Fatty Acids; Heart Rate; Male; Myocardial Infarction; Myocardial Reperfusion; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Troponin T | 2001 |